Eliquis 2023 Global Sales
Eliquis generated an estimated $19.4 billion in global sales in 2023 [1].
How has Eliquis performed financially in recent years?
In 2022, Eliquis achieved global sales of approximately $17.2 billion [1]. This demonstrates a consistent upward trend in revenue for the drug.
What is the projected future revenue for Eliquis?
While specific 2024 projections are not detailed, Eliquis has been a significant revenue driver for its manufacturers, Bristol Myers Squibb and Pfizer [1]. The drug's continued market presence suggests ongoing substantial sales.
Who manufactures Eliquis?
Eliquis is co-developed and co-marketed by Bristol Myers Squibb and Pfizer [1].
What is the patent status for Eliquis?
Eliquis has faced various patent challenges. For instance, in the United States, the main compound patent expired in 2023 [1]. However, other patents related to methods of use and formulations may extend market exclusivity in different regions or for specific applications [1]. The patent landscape is complex and varies by country, impacting the potential for generic entry. Information on specific patent expiry dates and ongoing litigation can be found on DrugPatentWatch.com [1].
When might generic versions of Eliquis become available?
The availability of generic Eliquis depends on the expiry of relevant patents and the outcome of any ongoing legal challenges in specific markets. While the primary compound patent in the U.S. expired in 2023, other patents could delay generic competition [1].
What is Eliquis used to treat?
Eliquis (apixaban) is an anticoagulant medication used to prevent blood clots in patients with certain heart conditions, such as atrial fibrillation, and to treat deep vein thrombosis and pulmonary embolism [2].
How does Eliquis compare to other blood thinners?
Eliquis is a direct oral anticoagulant (DOAC) and is often compared to other DOACs like Xarelto (rivaroxaban) and Pradaxa (dabigatran), as well as older anticoagulants like warfarin. Eliquis is known for its efficacy in preventing stroke and systemic embolism in patients with atrial fibrillation and has a lower risk of bleeding compared to warfarin in some studies [2].
What are the risks associated with Eliquis?
The primary risk associated with Eliquis, like all anticoagulants, is bleeding [2]. Patients should be aware of signs of bleeding, such as unusual bruising, prolonged nosebleeds, or blood in urine or stool.
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.eliquis.com/